CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

Cumulative X4 Pharmaceuticals Inc's Quick Ratio for Trailing Twelve Months Period

XFOR's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

XFOR Quick Ratio for Trailing Twelve Months Period

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 6.07 % -11.74 % 1.14 % 32.08 % 63.16 %
Y / Y Cash & cash equivalent Growth -33.56 % 77.43 % 198.26 % 40.61 % 48.82 %
Quick Ratio for Trailing Twelve Months Period 5.31 5.87 4.95 3.9 3.78
Total Ranking # 250 # # 434 # 568 # 786
Seq. Current Liabilities Growth -7.85 % 15.23 % 15.27 % -13.34 % -23.31 %
Seq. Cash & cash equivalent Growth -42.92 % 0.26 % 51.28 % -23.26 % 52.42 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2024
On the trailing twelve months basis Due to decrease in Current Liabilities in the I. Quarter to $22 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 5.31 below X4 Pharmaceuticals Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than X4 Pharmaceuticals Inc. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about XFOR
Quick Ratio XFOR in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 42
Sector # 206
S&P 500 # 361


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
11.55 6.21 3.46
(Jun 30 2020)   (Sep 30 2022)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Crispr Therapeutics Ag  14.34 
Ikena Oncology Inc   13.92 
Genenta Science S p a   13.43 
Invivyd Inc   13.42 
Krystal Biotech Inc   13.16 
Kymera Therapeutics Inc   13.01 
Protara Therapeutics Inc   12.95 
Anavex Life Sciences Corp   12.86 
Achilles Therapeutics Plc  12.56 
Autolus Therapeutics Plc  12.42 
Cabaletta Bio Inc   12.40 
Iteos Therapeutics Inc   12.28 
Rubius Therapeutics Inc   12.07 
Cardiff Oncology inc   10.29 
Caribou Biosciences Inc   10.19 
Allogene Therapeutics Inc   10.11 
Jasper Therapeutics Inc   10.11 
Scholar Rock Holding Corp  10.04 
Creative Medical Technology Holdings Inc   9.96 
Immunovant Inc   9.93 
Century Therapeutics inc   9.88 
Monte Rosa Therapeutics Inc   9.80 
Springworks Therapeutics Inc   9.52 
Elevation Oncology inc   9.27 
Solid Biosciences Inc   9.25 
Ambrx Biopharma Inc   9.16 
Avrobio Inc   9.12 
Vectivbio Holding Ag  8.95 
Candel Therapeutics Inc   8.73 
Passage Bio Inc   8.71 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com